版本:
中国

BRIEF-Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir

March 14 Abbvie Inc

* Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir/Pibrentasvir (G/P) for the treatment of all major genotypes of chronic hepatitis c

* Priority review follows EMA accelerated assessment and U.S. FDA priority review designations in December 2016 and January 2017 respectively Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐